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Abstract 
Background 
Previous reports suggest that omega-3 (n-3) polyunsaturated fatty acids (PUFA) supplements 
may reduce ADHD-like behaviour. Our aim was to investigate potential effects of n-3 PUFA 
supplementation in an animal model of ADHD. 
Methods 
We used spontaneously hypertensive rats (SHR). SHR dams were given n-3 PUFA (EPA and 
DHA)-enriched feed (n-6/n-3 of 1:2.7) during pregnancy, with their offspring continuing on 
this diet until sacrificed. The SHR controls and Wistar Kyoto (WKY) control rats were given 
control-feed (n-6/n-3 of 7:1). During postnatal days (PND) 25–50, offspring were tested for 
reinforcement-dependent attention, impulsivity and hyperactivity as well as spontaneous 
locomotion. The animals were then sacrificed at PND 55–60 and their neostriata were 
analysed for monoamine and amino acid neurotransmitters with high performance liquid 
chromatography. 
Results 
n-3 PUFA-feeding improved reinforcement-induced attention in males but not in female 
SHRs. Analysis of neostriata from the same animals showed significantly enhanced 
dopamine and serotonin turnover ratios in the male SHRs, whereas female SHRs showed no 
change, except for an intermediate increase in serotonin catabolism. In contrast, both male 
and female SHRs showed n-3 PUFA-induced reduction in non-reinforced spontaneous 
locomotion, and sex-independent changes in glycine levels and glutamate turnover. 
Conclusions 
Feeding n-3 PUFAs to the ADHD model rats induced sex-specific changes in reinforcement-
motivated behaviour and a sex-independent change in non-reinforcement-associated 
behaviour, which correlated with changes in presynaptic striatal monoamine and amino acid 
signalling, respectively. Thus, dietary n-3 PUFAs may partly ameliorate ADHD-like 
behaviour by reinforcement-induced mechanisms in males and partly via reinforcement-
insensitive mechanisms in both sexes. 
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Introduction 
Attention deficit hyperactivity disorder (ADHD) which affects ~5% of children [1] is 
characterized by attention deficit, hyperactivity and impulsiveness [2], with three times 
higher prevalence among boys than girls [3]. The etiology of ADHD is unknown, but meta-
analyses suggest a strong genetic component based on hereditary estimates in twin-studies of 
~76% [4]. Although high, the concordance of monozygotic twins is not perfect, suggesting 
that environmental factors may act in additive or interactive ways with the genetic influence 
[5,6]. 
The cognitive dysfunction in ADHD may be affected by a lack of omega-3 (n-3) 
polyunsaturated fatty acids (PUFAs) during embryonic development and early life [7-9]. 
Although humans are able to synthesize the omega-6 (n-6) fatty acid (FA) arachidonic acid 
(AA) from linoleic acid (LA), and the n-3 FAs like eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) from alpha-linolenic acid (ALA), these processes are slow and 
ineffective in most mammals [10], and they are also influenced by different factors like sex 
hormones, n-6/n-3 intake ratio and saturated fatty acid intake. Specifically, the capacity of 
males to transform ALA to DHA appears to be very low, and dietary access to DHA may 
thus perhaps be particularly important for males [11,12]. From the nutritional and 
anthropological point of view, humans have developed on a diet with a fair amount of n-3 
FAs, whereas many industrial diets contain little of these fatty acids [13]. 
A lack of n-3 PUFAs in the diet of children and, conversely, feeding of n-3 PUFA to 
pregnant women and mothers may influence cognitive abilities in the offspring [14-20], and 
potentially affect the prevalence of ADHD [21-23]. Experimental studies have suggested that 
dietary supplementation with n-3 PUFAs may enhance both synaptic development and 
function [9,24,25]. Different fatty acids in neurons and glia cells might change the properties 
of surface and intracellular membrane compartments, membrane-associated proteins, gene 
transcription, neurotransmitter metabolism and activities of synaptic vesicles and transporters 
[13,26,27]. Previous work has also indicated a possible link between ADHD and disturbances 
in dopaminergic function [28-32], with downstream connections to serotonergic and 
glutamatergic transmissions [33,34]. 
In the present study we employed the spontaneously hypertensive rat (SHR), a well validated 
genetically determined ADHD model [35-37], to examine whether increased access to n-3 
PUFAs during pregnancy and development may modulate behavioural symptoms and brain 
neurotransmitter metabolism [38]. Pregnant SHR dams and their offspring were fed extra n-3 
PUFAs, followed by behavioural testing of the offspring in standard operant chambers to 
monitor reinforcement-controlled levels of activity, impulsivity and attention [39]. Moreover, 
video-recordings of the animals during operant testing were used to assess general 
locomotion. Because activity-related behaviours in rodents may be influenced via 
neurotransmitter interactions between dopamine (DA), serotonin (5-HT) and glutamate (Glu) 
located in neostriatal synapses [33,34], we subsequently measured the levels of these 
transmitters and their metabolites in neostriatal extracts from the very same SHR animals 
which had been studied behaviourally. Our results indicate that n-3 PUFA feeding may 
ameliorate reinforcement- and monoamine-dependent ADHD symptoms in a sex-specific 
manner, whereas other symptoms, independent of reinforcement and possibly correlated to 
changes in amino acid transmitters, were ameliorated to the same extent in both sexes. 
Methods 
Animal models 
The study was approved by the Norwegian Animal Research Authority, and conducted in 
accordance with the laws and regulations controlling experiments on live animals in Norway. 
Spontaneously Hypertensive Rodents (SHR/NCrl) purchased from Charles River, Sulzfeld, 
Germany, were used as breeding subjects. During the first three weeks of life, the rats were 
under veterinarian care at the Norwegian Defence Research Establishment (Kjeller, Norway). 
Dams were caged singly under standard conditions (temperature ~22 °C, humidity ~55%, 12 
h light/dark cycle), with free access to water. The veterinarian administered feeding of either 
n-3 PUFA-enriched diet or chow to dams before breeding, under pregnancy and after birth. 
At postnatal day (PND) 25, 36 rats were shipped to the University of Oslo for behavioral 
testing. Thereafter, offspring of both sexes were fed similar diets as their parents, until 
sacrifice at PND 55–60. The weight was measured continously on SHR-rats from each 
experimantal group troughout the study. In order to obtain the growth rate, body weight was 
measured continuously on SHR-rats from each experimental group throughout the study. In 
the males, the n-3 PUFA diet increased the growth rate by 7.7% compared to the control-diet 
(with p = 0.01 and n = 8 and n = 11 respectively). Whereas n-3 PUFA diet had no effect on 
the female growth rate (p = 0.1, control diet; n = 10 and n-3 PUFA diet; n = 7). 
Experimental diet 
The experimental group was given a semi-synthetic n-3 enriched feed, as described in 
Rokling-Andersen et al. 2009 [40]. This feed was high on the essential n-3 PUFAs EPA and 
DHA with 9.1% (w/w) lard and 10.4% Triomar (EPAX5500) delivered by Pronova Biocare, 
Lysaker, Norway. Triomar contained 55% of total n-3 FA as TAG including EPA, 300 mg/g; 
DHA, 190 mg/g; total n-3 FA, 580 mg/g (made up of EPA, DHA, ALA, stearidonic acid, 
eicosatetraenoic acid, heneicosapentaenoic acid, and docosapentaenoic acid). This dose 
represents about 3.6% of total energy intake of the rats and is comparable to traditional Inuit 
intake of marine FA [15]. In addition, 1.5% of soybean oil (Mills Soyaolje; Denofa Lilleborg, 
Fredrikstad, Norway) was provided to avoid essential n-6 FA deficiency. 
The dietary composition (g/100 g food) was: total fat, 21; sucrose, 20; starch, 31.5; protein, 
20; cellulose, 1; vitamin mixture, 1.5 and salt mixture, 5. Vitamin (Cat No: 904654) and salt 
mixture (Cat No: USP XVII) was bought from MP Biochemicals LLC. The feed was kept at 
−20 °C and given to the rats in portions sufficient for 1 day supply. 
Control-feed 
The control SHRs were given lab chow (RM3 (E) from Special Diet Services, Witham, Essex 
CM8 3 AD, UK, www.sdsdiets.com/pdfs/RM3-E-FG.pdf). This feed is low on EPA and 
DHA, and has a n-6 to n-3 ratio of about 7:1. The fatty acid composition of this feed (w/w) 
were as follows: saturated fatty acids: lauric acid, 0.5 mg/g; myristic acid, 2 mg/g; palmitic 
acid, 3.6 mg/g; stearic acid, 0.9 mg/g and monounsaturated fatty acids: myristoleic acid, 0.1 
mg/g; palmitoleic acid, 1.3 mg/g; oleic acid, 10.3 mg/g and PUFAs: LA, 11.5 mg/g; ALA, 
1.7 mg/g; AA, 2.2 mg/g; docosapentaenoic acid, 0.4 mg/g. The dietary composition (g/100 g 
food) was: total fat, 4.2; sucrose, 5.7; starch, 33.9; protein, 22.4; cellulose, 3.9; hemicellulose, 
9.2; dietary fibre, 15.4; vitamin mixture, 0.5 and salt mixture, 4.6. The diet was kept at −20 
°C until fed to the animals. 
Behavioural analyses 
At PND 21 the offsprings were moved to a separate location for behavioural testing. All 41 
sessions included habituation, training, shaping and testing with reinforcers. The duration and 
reinforcement scedule of the different sessions is described in the summary of the 
experimental procedure (table 1). Sessions used in the analyses lasted for 90 min. 
Table 1 The reinforcement was given using either a fixed time schedule of 
reinforcement (FT), continuous reinforcement schedule (CRF) or a variable interval 
schedule of reinforcement (VI) 
Behavioral procedure Session number Reinforcement schedule 
Habituation, 30 min 1  
Magazine training, 30 min 2 – 3 FT 10 seconds 
Flap training 4 – 5 CRF 
Shaping of lever-pressing 6 – 7  
30 minutes session 8 – 13 VI 3 seconds 
90 minutes session, 16 chambers 14 – 41 VI 180 seconds 
A total of 36 animals were tested using a two-lever visual discrimination task [39] with one 
session each day for 34 days (the last 28 sessions were used in the analyses). The animals 
were also video-recorded during the operant task in sessions 13, 24, and 34 to monitor 
spontaneous locomotion, and the results were averaged for each rat. The n-3 PUFA-fed group 
included 8 males and 7 females, whereas 11 males and 10 females served as control-fed 
reference animals. Testing of the experimental and control groups took place at different time 
points. During habituation and response acquisition, two offsprings were housed in one 
transparent cage 41 × 25 × 25 cm (height), whereas during response acquisition and 
throughout the rest of the study, the animals were housed individually in the same type of 
cages. The rats had free access to water during the habituation sessions, following which they 
were deprived of water for 21 h a day throughout the rest of the study. The behavioural 
testing took place between 0900 and 1400 h. 
Table 1: Summary of the behavioural procedures and reinforcement schedule. 
Apparatus 
The animals were tested in 16 operant chambers (Campden Instruments) enclosed in sound-
resistant outer housings [39,41]. The chambers were ventilated and equipped with a grid 
floor, and the animals’ working space was 25 × 25 × 30 (height) cm. The chambers were 
equipped with two retractable levers requiring a dead weight of at least 3 g to activate a 
micro-switch. A 2.8 W cue light was located above each lever. The reinforcer (0.05 mL tap 
water) was delivered by a liquid dipper located in a small recessed cubicle, where a 2.8 W 
cue light lit up. A 7 × 5 cm transparent plastic top-hinged flap separated the cubicle from the 
animal’s working space. The computer program LabVIEW 7.1 (National Instruments 
LabVIEW, Austin, Texas, USA, 2004) recorded the behaviour and scheduled reinforcements 
and lights. Each operant chamber was equipped with a video camera (Mini Color Hidden 
Cameras (420TVL, 0,1lux) from Tracer Technology Co. Ltd, Taiwan) positioned to capture 
the entire working space, in the upper rear corner of the ceiling at an angle of 45 o. The DVR 
Live Capture computer program (Novus Security, 2009, Warsaw, Poland) controlled the 
cameras and saved the video files for analyses. 
Operant testing 
Prior to behavioural testing, the rats were semi-randomly assigned an operant chamber. 
Following habituation in the operant chamber, the animals were trained to lever-press and 
then run for additional sessions to strengthen the newly learned behaviour. In the operant 
task, two levers were used. Pressing the lever, which was signalled by a lit cue light located 
above the lever, produced reinforcements according to a variable interval 180 s schedules of 
reinforcement (VI 180 s). During this period, the cue light above the alternative lever was off, 
and lever press had no consequences. During reinforcer delivery, the cue light above the lever 
was turned off, and a 2.8 W cue light was lit in the water cubicle. The lever producing 
reinforcers alternated unpredictably between the two lever-alternatives, but stayed the same 
until a reinforcer was produced by a lever-press. Following reinforcer delivery, the computer 
program semi-randomly selected which lever would produce the next reinforcer. To avoid 
development of lever-preferences, the program allowed a maximum of four consecutive 
reinforcers on the same lever. 
Measure of reinforcement-controlled behaviour 
Recording was made of number of presses on the reinforcer-producing lever and on the 
alternative lever, number of reinforcers produced and collected, and the time of the events. 
Percentage of responses on the lever producing reinforcers (for all responses, and for the first 
response following reinforcer delivery), and the time between two responses (inter-response 
time, IRT), were calculated. Attention was operationalized as the percentage of responses on 
that lever which produced reinforcers (the animal had to pay attention to and press the lever 
signalled by the lit cue light above the lever, i.e. stimulus control). Hyperactivity was 
operationalized as the total number of lever-presses on the two levers combined. The IRTs 
were split into responses with IRTs longer than 0.67 s and shorter than 0.67 s. Number of 
responses with short IRTs (< 0.67 s) was used as a measure of impulsivity (“premature 
responding” or “inability to wait”). 
Video recordings 
The animals were video-recorded during the operant task in 3 sessions, which were chosen to 
represent the spontaneous activity early, in the middle of and late in the experimental testing 
period. The cameras recorded 15 frames per second, and frame-to-frame analyses of changes 
in pixels, which occurred whenever the animal moved, were performed by using the 
computer program Musical Gestures Toolbox for audio and video analysis [42]. The total 
number of pixel-changes was used to quantitate movements. Each of the 3 sessions was 
divided into 5 segments in order to analyse within-session changes in locomotion in the 
experimental and control groups. To reduce noise, pixel-changes were averaged across 15 
frames and a noise reduction threshold (0.25) and filter (8) were used. 
Analysis of behavioural data 
All statistical analyses were performed in Statistica 6.0 (StatSoft. Statistica for Windows, 
StatSoft Inc., Tulsa, OK, 2005). Data were evaluated either by multivariate analyses using 
Wilks lambda (MANOVAs) when the degrees of freedom relative to the number of levels of 
the repeated factor permitted this approach, or by univariate analyses of variance (ANOVAs), 
adjusting the degrees of freedom with the Huynh–Feldt epsilon [43]. Sessions were used as 
the within-individual factor in the operant task, whereas sessions and segments were used as 
the within-individual factor in the video analyses. n-3 PUFA-feeding was used as the 
between-individuals factor in both analyses. Session were included as a factor to look for 
changes in behaviour across development. Post-hoc tests on main effects were performed 
using the Unequal N HSD test. Preparation of graphs was performed using Prism (GraphPad 
Software Inc.) and the graphs represent means ± SEM for each group (n = 7–11). 
Biochemical analyses 
Chemicals 
Monoamine and amino acid analyses were done with high performance liquid 
chromatography (HPLC). L-amino acid standards, including aspartic acid (Asp), glutamic 
acid (Glu), serine (Ser), glutamine (Gln) and glycine (Gly) were obtained from Pierce 
(Rockford, Ill., USA), whereas taurine (Tau), γ-amino butyric acid (GABA), and α-amino 
adipic acid were from Sigma (Sigma-Aldrich, Steinheim, Germany). The monoamine 
standards dopamine (DA), homovanillic acid (HVA), serotonin (5-HT), 5-hydroxyindole-3-
acetic acid (HIAA) and 3,4-hydroxybenzylamine (DHBA), as well as HClO4 and ascorbic 
acid were also obtained from Sigma. The BCA-assay kit (Thermo-Scientific, Rockford, 
USA), and n-hexane (Merck, Darmstadt, Germany) were bought from VWR. Solutions were 
made with purified distilled water (Milli-Q Advantage A10, Millipore). 
Sample collection 
Following behavioural testing, the SHR rats as well as age-matched Wistar Kyoto rats 
(WKY/NHsd) [37] were stunned and rapidly decapitated at PND 55–60 (the WKY/NHsd 
were used as additional reference strain in the biochemical analyses). The neostriata were 
removed, frozen in liquid N2, and stored at −70 °C until sample preparation and analyses. 
Extract preparation and protein assay 
The tissues were rapidly weighed and homogenized by hand with 20 strokes in 500 µL ice 
cold 0.2 M HClO4, using a glass/teflon Potter-Elvehjem homogenizer. This suspension was 
mixed with an equal volume of DHBA (used as internal standard for monoamines) in 0.12 
mM ascorbic acid to a final concentration of 0.227 µM DHBA. The homogenates were 
centrifuged for 20 min at 15000 × g at 2 °C in a Sorvall RMC-14-microcentrifuge. The 
pellets were frozen at −40 °C for later protein determination, performed by dissolving pellets 
in 0.1 M NaOH and measuring protein content by the BCA assay [44]. The supernatants were 
extracted with equal volumes of n-hexane to reduce lipid contamination, and the top layer 
was discharged. For amino acid analyses, parts of the delipidized HClO4 extracts were mixed 
with a solution of α-amino adipic acid (used as internal standard) to a final concentration of 
10 µM in a total volume of 1.9 mL. These extracts were neutralized to pH 7.2 with ice cold 
KOH and centrifuged for 20 min at 15000 × g at 2 °C as described above. The supernatants 
were stored at −70 °C until analyses. The samples were then transferred into glass-vials by 
filtering through Nylon-66 micro filters (0.22 µm) from Nalgene (Rochester, New York, 
USA), before HPLC analysis. 
Monoamine analysis 
Column and mobile phases were selected for analysis of catecholamine content in plasma and 
was supplied by Chromsystems (Germany). The frozen extracts were used directly for 
analyses of total DA and 5-HT, as well as their metabolites HVA and 5-HIAA, using a 
reversed-phase HPLC (Shimadzu, Kyoto, Japan) with electrochemical detection (ECD; 
Decade II with Sencell flow electrode, Antec Leyden) set to a working potential of 0.6 V. 
Each sample was eluted for 40 min with a flow rate at 1.3 mL/min and a representative 
chromatogram is shown in Figure 1b. External standard solutions of DA, HVA, 5-HT, 5-
HIAA and DHBA were analysed on the same day. The chromatograms were analysed using 
the software Lab Solutions (Shimadzu). Monoamine concentrations are expressed in 
pmol/mg total neostriatal protein. 
Figure 1 Chromatographic profiles of rat neostriatal extracts. (a) Amino acids in a WKY 
control-fed female, and (b) monoamines in a control-fed SHR male. Panel a) shows the peaks 
of aspartic acid (asp), glutamate (Glu), serine (Ser), glutamine (Gln), α-amino adipic acid 
(AAA), glycine (Gly), taurine (Tau) and γ-amino butyric acid (GABA). Panel b) shows the 
peaks of 5-hydroxyindol-3-acetic acid (5-HIAA), homovanillic acid (HVA), 3,4-
hydroxybenzylamine (DHBA), dopamine (DA) and serotonin (5-HT) 
Amino acid analysis 
Using a Chromspher 5 C18 column of 25 cm length and 4.6 mm inner diameter (Varian), 
total amino acids in the neostriatum extracts were analysed [45], using reversed-phase HPLC 
fitted with a fluorescence detector (Shimadzu, Kyoto, Japan) after derivatization with o-
phthaldialdehyde (OPA; Sigma). The mobile phase comprised 75% 50 mM phosphate buffer, 
pH 5.25, and 25% methanol (v/v), changing linearly to 25% phosphate buffer and 75% 
methanol during 26.5 min, after which the methanol concentration was linearly reduced to 
15%. Each sample was eluted for 45 min with a flow rate at 0.4 mL/min and a representative 
chromatogram is shown in Figure 1a. A mixture of the amino acids of interest was used as 
external standards in a concentration of 100 µM. The chromatograms were analysed using the 
software Lab Solutions (Shimadzu). Amino acid concentrations are expressed in nmol/mg 
total neostriatal protein. 
Statistical analysis 
Statistical significance of biochemical differences between samples was determined by 
unpaired, two-tailed Student’s t-test, where p < 0.05 is defined as significant. Level of 
significance is symbolized with * (p-value ≤ 0.05), ** (p-value ≤ 0.01 and *** (p-value ≤ 
0.001). Statistical analyses as well as preparation of graphs were performed using Prism 
(GraphPad Software Inc), and the graphs display the means ± SEM for each group (n = 4–8). 
Results 
Behavioural analysis 
Operant testing 
Overall, n-3 PUFA supplementation interacted with sex in the SHR animals, improving 
percentage of presses on the lever producing reinforcers (stimulus control) in n-3 PUFA-fed 
males, but having the opposite effect in females (Figure 2a-2b). Analyses of stimulus control 
for all lever presses showed a statistically significant main effect of session (F(2,31) = 11.31; 
p < 0.01). Trends were observed for a main effect of sex (F(1,32) = 3.45; p = 0.07), and for a 
sex × feed condition interaction (F(1,32) = 3.66; p = 0.06). Analyses of stimulus control for 
the first lever press following reinforcer delivery (Figure 2a) also showed a statistically 
significant sex × feed condition interaction effect (F(1,32) = 5.99; p = 0.02). No significant 
effects were found in the Unequal N HSD post-hoc analyses of the significant sex × food 
condition interaction effect. 
Figure 2 Analysis of reinforcement-controlled behaviour. (a) Attention (stimulus control; 
percentage of responses on the reinforcer-producing lever) for the first lever-press following 
reinforcer delivery (sex × supplementation, F1,32 = 5.99, p = 0.02); (b) Attention (stimulus 
control; percentage of responses on the reinforcer-producing lever) for all responses (sex × 
supplementation, F1,32 = 3.66, p = 0.06); (c) Impulsivity (‘premature response’, lever presses 
with inter-response times <0.67 s) (sex × supplementation, F1,32 = 5.81 p = 0.02); (d) Lever-
directed hyperactivity (all lever-presses) (sex × supplementation, F1,32 = 4.94, p = 0.03). 
Data are presented as means ± SEM (n = 7–11) 
No statistically significant effects were observed during analyses of number of reinforcers 
collected. Out of the possible 30 reinforcers per session, the mean number of reinforcers 
collected was similar in all groups across sessions, and ranged from 28.3 (n-3 PUFA-treated 
males, session 27) to 29 (control-fed male SHRs, session 6). 
Number of responses with short IRTs was decreased in n-3 PUFAs supplemented males but 
increased in n-3 PUFA supplemented females (Figure 2c). The analyses showed a significant 
main effect of session (F(2,31) = 4.23; p = 0.02) and a significant sex × feed condition 
interaction (F(1,32) = 5.81; p = 0.02). Also, a significant sex × feed condition × session 
interaction was found (F(2,31) = 5.60; p < 0.01). No significant effects were observed in the 
post-hoc analyses of the significant sex × feed condition interaction effect using the Unequal 
N HSD test. 
Supplementation with n-3 PUFAs reduced lever-directed hyperactivity in males and 
increased hyperactivity in females (Figure 2d). The analyses showed significant main effects 
of sex (F(1,32) = 6.23; p = 0.02), session (F(2,31) = 8.62; p < 0.01) and a significant sex × 
feed condition interaction (F(1,32) = 4.94; p = 0.03). Unequal N post-hoc analyses of the 
significant sex × food condition interaction showed that control-fed SHR males emitted 
significantly more lever-presses than control-fed female SHRs (p = 0.01). 
Locomotor testing 
Analyses of video data showed that n-3 PUFA-supplemented rats had reduced locomotion in 
the initial segments of the sessions in both males and females (Figure 3). The analyses 
showed significant main effects of session (F(2,30) = 8.63; p < 0.01) and segment (F(4,28) = 
14.77; p < 0.001,) as well as significant sex × segment (F(4,28) = 3.29; p < 0.03), feed 
condition × segment (F(4,28) = 4.63; p < 0.01) and session × segment (F(8,24) = 6.31; p < 
0.001) interaction. In addition, the analyses showed a significant sex × feed condition × 
session interaction (F(2,30) = 3.54; p = 0.04) and a significant food condition × session × 
segment interaction (F(8,24) = 2.44; p = 0.04). This means that all the SHRs increased their 
general activity between early and middle session, and within sessions there was a decrease 
in general activity across segments. The males showed more general activity across segments 
relative to female SHRs. Comparison of general movement for PUFA-supplemented SHR vs. 
SHR control showed that general movement was significantly different for the first segment, 
using unpaired two-tailed Student’s t-test. 
Figure 3 Analysis of general locomotion. Video analyses of pixel-changes showed that n-3 
PUFA supplementation reduced locomotion in the initial 18 min segments of the 90 min 
sessions in both males and females. For the first segment, comparison of general movement 
for PUFA-supplemented SHR vs. SHR control is significantly different, as symbolized by * 
(p ≤ 0.05), using unpaired two-tailed Student’s t-test. Data are presented as means ± SEM (n 
= 7–11) 
Behavioural summary 
Taken together, n-3 PUFA supplementation significantly enhanced reinforcement-controlled 
attention (Figure 2a-b) and reduced lever-directed hyperactivity (Figure 2d) and impulsivity 
in SHR males (Figure 2c), whereas the opposite or no effects were observed in females 
(Figure 2c-d). In contrast, general locomotion was reduced by n-3 PUFA-feeding to a similar 
extent in both sexes (Figure 3). 
Biochemical analyses 
Monoamine transmitters 
Dietary supplementation with n-3 PUFA to the dams and offspring changed DA and 5-HT 
dynamics in the SHR neostriata in a sex-specific manner, with significant effects in the male 
SHR offspring only. DA levels were reduced by 30 ± 11% in the n-3 PUFA-fed male SHRs 
(n = 4) as compared to control-fed male SHRs (n = 8), p = 0.03. In all other animals, DA 
levels remained similar to the WKY controls (Figure 4a). In the neostriatum, DA is 
exclusively present in the terminals of the nigrostriatal fibers, with DA levels representing a 
balance between DA release, DA reuptake/synthesis and DA degradation. Thus, we 
compared levels of DA with the DA degradation product HVA, a measure indicating 
biochemical DA utilization in dopaminergic synapses [46,47]. Males fed n-3 PUFA showed a 
80 ± 18% increase in HVA levels (n = 4) in neostriatum (Figure 4b), leading to a HVA/DA 
ratio of 0.22 ± 0.04 in the male SHR, which was more than twice that obtained in the female 
SHR and the control-fed SHR and WKY (Figure 4c). 
Figure 4 Dopamine (DA) and homovanillic acid (HVA) levels in neostriatum. n-3 PUFA 
supplementation modulated DA turnover in male SHR: (a) DA and (b) HVA levels were 
used to determine (c) HVA/DA ratios. Data are presented as means ± SEM (n = 4–8) and the 
level of significance is symbolized by * (p-value ≤ 0.05), ** (p-value ≤ 0.01) or *** (p-value 
≤ 0.001). The p-values are calculated by comparison with the mid bar representing control-
fed SHRs. The analyses were performed by HPLC using electrochemical detection 
Similar to the DA system, 5-HT in the neostriatum is exclusively present in nerve terminals 
[28]. In the WKY controls, total 5-HT levels were similar in both sexes, whereas in the 
SHRs, they were slightly higher in control-fed males than females. This sex difference was, 
however, obliterated by n-3 PUFA supplementation, with 5-HT levels decreasing by 40 ± 
18% in the males (n = 4) as compared to control-fed SHR (n = 8, p = 0.06), whereas the 
female 5-HT levels remained unchanged after n-3 PUFA supplementation. At the same time, 
n-3 PUFA feeding enhanced the levels of the degradation product 5-HIAA [28] in both sexes 
(Figure 5b), with the 5-HIAA/5-HT ratios indicating 5-HT turnover rates of 4.8 ± 1.7 (n = 4) 
and 4.5 ± 1.2 (n = 4) in the male and female n-3 PUFA-fed SHRs, respectively. In contrast, 
control-fed male and female SHRs had ratios of 1.3 ± 0.4 and 3 ± 1.1, respectively, whereas 
WKY controls of both sexes showed ratios of 1.1 ± 0.1 (n = 5) and 1.2 ± 0.1 (n = 5), 
respectively (Figure 5c). Thus, PUFA-feeding enhanced 5-HT utilization in the SHRs to the 
same levels in both sexes. Interestingly, the statistically significant effect was restricted to the 
males, whereas the female SHR showed a partial increase already without PUFA 
supplements. 
Figure 5 Serotonin (5-HT) and 5-hydroxyindole-3-acetic acid (5-HIAA) levels in 
neostriatum. n-3 PUFA supplementation modulates 5-HT turnover in both male and female 
SHR rats. Levels of (a) 5-HT and (b) 5-HIAA were used to determine (c) 5-HIAA/5-HT 
ratios. The data are presented as means ± SEM (n = 4–8) and the level of significance is 
symbolized with * (p-value ≤ 0.05), ** (p-value ≤ 0.01) or *** (p-value ≤ 0.001). The p-
values are calculated by comparison with the mid bar, which represents control-fed SHRs. 
The analyses were performed by HPLC using electrochemical detection 
Amino acid transmitters 
Supplementation with n-3 PUFA also modulated amino acid transmitters in the neostriata. 
Recent studies suggest that Gln/Glu ratios may indicate the efficacy of presynaptic 
glutamatergic signalling in vivo [48,49], In our study, levels of the major excitatory 
transmitter Glu were reduced in n-3 PUFA-fed SHRs of both sexes, with males showing a 
significant reduction of 22% (n = 4, p = 0.02). And a similar effect occurring in the females 
(Figure 6a). In contrast, levels of the precursor/metabolite amino acid Gln remained stable in 
SHRs of both sexes (Figure 6b), leading to significantly higher Gln/Glu ratios in both sexes 
of n-3 PUFA-fed SHRs when compared to control-fed SHRs. Specifically, control SHRs of 
both sexes had a Gln/Glu-ratio of 0.5, whereas n-3 PUFA-fed SHRs of both sexes showed a 
significant 21% increase of Gln/Glu ratios (p = 4.9 × 10-4). These latter results approached 
those observed in the WKY controls, where both sexes showed a 33% higher Gln/Glu ratio 
than that observed in the control-fed SHRs (p = 3.2 × 10-4), with a mean value of 0.7. Hence, 
n-3 PUFA-feeding appeared to reverse the abnormally low Gln/Glu ratio in the control-fed 
SHRs towards control WKY-values in both sexes of the SHR animals (Figure 6c). Thus, our 
data suggest that control-fed SHR animals had a subnormal glutamatergic activity, and that 
this was partly normalized in the n-3 PUFA-supplemented animals. 
Figure 6 Glutamate (Glu) and glutamine (Gln) levels in neostriatum. n-3 PUFA 
supplementation modulates Gln/Glu turnover in both male and female SHR rats. Levels of (a) 
Glu and (b) Gln were used to determine (c) Gln/Glu ratios. Control-fed SHRs of both sexes 
showed significant ratio reductions when compared to WKY controls, and n-3 PUFA feeding 
reversed these ratios in both SHR sexes. Data are presented as means ± SEM (n = 4–8) and 
the level of significance is marked with * (p-value ≤ 0.05), ** (p-value ≤ 0.01) or *** (p-
value ≤ 0.001). The p-values are calculated by comparison with the mid bar representing 
control SHRs 
In addition to these changes in the major neurotransmitter monoamines and amino acids, 
minor effects were also seen in glycine (Gly). This bifunctional amino acid, which is active 
both as an inhibitory transmitter in the brain stem and spinal cord, and as an obligatory co-
ligand of the NMDA-type of Glu receptor in excitatory synapses [50,51], was significantly 
increased after n-3 PUFA-supplementation in both SHR sexes. When compared to the male 
and female WKY controls, neostriatal Gly levels were significantly lower in control-fed 
SHRs of both sexes (by 42 and 28%, p = 2.4 × 10-4 and p = 0.04), respectively (Figure 7). 
Following n-3 PUFA supplementation, Gly levels were changed to a level similar to what 
was seen in WKY neostriata, by 24 and 28% increases (p = 0.03 and p = 0.05), respectively. 
Thus, our observations imply both a genetic difference between the Gly systems in the SHR 
and WKY strains and an effect of n-3 PUFAs on the metabolism of neostriatal Gly in the 
SHRs. 
Figure 7 Concentrations of amino acids in neostriatal extracts. Both male and female 
control-fed SHRs showed significantly reduced levels of glycine (Gly) when compared to 
WKY controls, and n-3 PUFA supplementation increased Gly levels significantly in both 
SHR sexes. In contrast, GABA levels from SHR controls were significantly lower than in 
WKY controls of both sexes, and n-3 PUFA supplementation did not change the level of 
GABA. Taurine (Tau) levels were significantly lower in the male SHR controls than in the 
male WKY controls. n-3 PUFA supplementation promoted a small, non-significant decrease 
in Tau levels in both sexes. Aspartate (Asp) and serine (Ser) remained unchanged. Data are 
presented as means ± SEM (n = 4–8), and the level of significance is symbolized with * (p-
value ≤ 0.05), ** (p-value ≤ 0.01) or *** (p-value ≤ 0.001). The p-values are calculated by 
comparison with the mid bar representing control-fed SHRs 
In contrast to the glycinergic system, n-3 PUFA feeding had no significant effect on GABA 
levels in the SHR of either sex. Hence, the diet-induced major changes in excitatory 
glutamatergic fibers as well as the modulatory dopaminergic and serotoninergic synaptic 
inputs to the neostriatal cells seen in the SHR animals (see above), did not lead to major 
changes in the local GABAergic transmission present in neostriatum. 
Finally, the levels of Asp and Ser were unchanged by dietary n-3 PUFAs in both male and 
female SHRs. Moreover, although the concentration of taurine (Tau) appeared to respond to 
n-3 PUFA feeding by decreasing levels in both male and female SHRs, these changes were 
not significant (p = 0.08 and 0.065 respectively). A potential effect of Tau in modulating DA 
release in the ventral striatum, of importance for reinforcement mechanisms [52] and possibly 
ADHD in the SHR, therefore remains uncertain. These data also support the idea that n-3 
PUFA supplementation predominantly affects synaptically active amino acids and not general 
amino acid metabolism. 
Discussion 
In this study, dietary n-3 PUFA supplementation to SHRs was associated with two distinct 
types of changes in ADHD-like behaviours which occured in synchrony with changes in 
neurotransmitter systems. One of these included reduced levels of reinforcer-controlled 
activity, impulsiveness and inattention in male SHR, with no or opposite effects in the female 
SHRs. Neurotransmitter dynamics in neostriatum of these animals were also changed, 
showing enhanced DA and 5-HT turnover, which again were predominantly seen in male 
SHRs. In contrast, the other change included a reduction in general locomotor activity in both 
SHR sexes, which appeared to correlate with changes in levels of several neuroactive amino 
acids in both male and female SHRs. Thus, our data indicate major sex-specific effects on 
neurotransmitter systems in the PUFA-fed animals, with the males having unique 
enhancements of both DA and 5-HT in the neostriatum [53]. Although the 5-HT degradation 
product 5-HIAA also was significantly increased in females, with a similar turnover ratio to 
that seen in males, the turnover in female SHRs was not statistically significant. Even though 
the mechanisms behind these effects of n-3 PUFAs are unclear [9,27,54,55], our data 
correlate well with the behavioural observations, which also showed sex differences, with 
males improving on all operant measures, whereas females did not. This similarity suggests a 
possible causal relation between the n-3 PUFA-induced increase of modulatory 
neurotransmission [56] and improved behaviour [36]. 
Reinforcement mechanisms in the CNS are mostly mediated via DA synapses [57-59], which 
are heavily concentrated in neostriatal brain regions, particularly in the dorsal and ventral 
caudate-putamen [60]. Here, excitatory Glu inputs from cerebral cortex and thalamus 
predominantly terminate on efferent GABAergic cells, with the widely distributed DA and 5-
HT modulatory synaptic inputs from the brain stem having the ability to modulate the 
efficacy of the Glu-to-GABA synapses, thereby determining to what extent efferent 
GABAergic information will be transmitted out of the basal ganglia [61]. This synaptic 
effect, mediated trough an undefined mechanism being involved in the neurobiological 
changes occurring in the n-3 PUFA-fed animals, may suggest enhanced action potential firing 
frequencies, structural synaptic changes (e.g. increased number of vesicles or synapses) or 
enhanced biochemical capacity, vesicle storage capacity or enhanced neurotransmitter levels 
[62-66]. 
In contrast, effects on locomotion appear to represent a distinct target, with general, non-
operant locomotion activities being sensitive to n-3 PUFAs in both sexes. Given that the 
locomotion occurred continuously during the operant test, and that frame-to-frame analyses 
of video-recordings detected changes in pixels whenever the animals moved, it is clear that 
this measure reflected both operant behaviour controlled by the scheduled reinforcers as well 
as general movements. The interpretation that operant behaviour and video-measured 
locomotion represent two distinct phenomena is also supported by the dissociation of 
reinforcement-controlled lever pressing and changes in the video-measured locomotion 
observed in female SHRs, where n-3 PUFA feeding increased levels of operant responses but 
reduced initial video-measured locomotion. 
Because the PUFA-induced reduction in non-operant behaviour locomotor activity occurred 
in both sexes, it is of great interest that those neuroactive transmitter amino acids which 
responded to n-3 PUFAs also showed similar patterns in the two sexes. Specifically, these 
included reduced plasma levels of Glu and enhanced levels of Gly, with no changes in Gln 
and GABA. Because the Gln/Glu ratio was significantly increased, glutamatergic 
neurotransmission in neostriatum of the SHRs may be enhanced by dietary n-3 PUFA 
supplementation in both sexes. Previous analysis has suggested that motor activity may be 
modulated by Glu receptor activation [33], in agreement with our observations. 
The levels of Gly showed similar differences as those found in the Gln/Glu ratios; with low 
levels in the control-fed SHRs, and PUFA-induced increase in levels seen in both SHR sexes. 
Although Gly receptors are present in the rat striatum, and are proposed to modulate both 
cholinergic, dopaminergic and glutamatergic transmission [67-69], the importance of 
increased Gly levels in the striata of n-3 PUFA supplemented SHRs remains unknown [70-
73]. Previous work has also indicated changes in Tau levels in male SHRs when compared to 
WKY controls [74], suggesting a possible role for Tau in association with ADHD. Indeed, 
Tau changes may lead to impaired regulation of Gly, GABA and/or DA signalling [52,75-
78]. However, Tau levels were only insignificantly reduced following n-3 PUFA feeding, 
making it unlikely that these changes represent an important mechanism for mediating n-3 
PUFA-induced amelioration. 
Finally, the PUFA-induced normalization of the Gln/Glu ratios as well as Gly levels, which 
occur in both female and male SHRs, is of considerable interest. This contrasts to the major 
PUFA-induced changes found in the DA and 5-HT turnover, seen predominantly in the male 
SHRs. Intuitively, these dietary effects of n-3 PUFA in ADHD models like SHR would be 
expected to normalize both groups of neurotransmitters. However, given the well-known 
distinct functional organizations of the quantitatively predominant amino acidergic synapses 
in the neostriatum as compared to the minor but widespread modulatory monoaminergic 
synaptic systems [79], our data appear consistent with the interpretation that n-3 PUFA 
feeding induced strong activation of the modulatory DA and 5-HT systems in order to 
normalize the functionally more important amino acidergic neurotransmitter systems. It 
should also be emphasized that our study only represents a small number of possible factors 
involved in ADHD-development. Moreover, other studies have also observed sex differences 
in other important neurochemical parameters like the dopamine D1 and D2 receptors [80], or 
monoamine-catabolizing enzymes like COMT [81,82]. Finally, a potential weakness of our 
study is that the control group is fed considerably less fat than the n-3 PUFA-fed group. 
However, recent studies [83] demonstrated that adult male Long Evans rats given a high-fat 
diet developed a decrease, not an increase in their DA turnover in the ventral striatum, 
making it highly unlikely that the high-fat diet per se employed in this study is responsible 
for the enhancement of DA turnover which occures in the male SHRs.. 
Conclusion 
Our study indicates that dietary supplementation of n-3 PUFA to SHR dams and their 
offspring induces two distinct sets of changes in the offsprings: The first included activation 
of presynaptic neostriatal DA and 5-HT signalling as well as several reinforcement 
mechanisms [84], all restricted to the male SHR, suggesting that this effect may preferentially 
improve male ADHD-like symptoms; In contrast the second included a non-reinforcement 
but PUFA-induced improvement in behavioural responses in both male and female ADHD 
animals, and changing amino acid transmitters to the same extent in both sexes. Thus, n-3 
PUFA may partly ameliorate ADHD-like behaviour via reinforcer-induced systems restricted 
to males, and partly via reinforcer-insensitive systems present in both sexes. 
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